Safety and Efficacy of Xalkori ROS1
← catalyst calendarNCT03375242 · readout in 79 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
97actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-10-25 | actual | When the study began enrolling |
| Primary completion | 2026-11-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-06 | estimated | The whole study's end, after follow-up |
| First posted | 2017-12-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer
Intervention
- Drug: crizotinib — also filed as XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg
Primary outcome
what the primary-completion date above is the date OFThe incidence of adverse drug reactions in this surveillance.
measured 52 weeks
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed